RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Carlos Jiménez to Administration, Oral

Back to Details
This is a "connection" page, showing publications Carlos Jiménez has written about Administration, Oral.
Carlos Jiménez
Connection Strength
0.043
Administration, Oral
  1. Masanas M, Masi? N, Su?rez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jim?nez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guill?n G, Navarro A, Llobet-Navas D, Villanueva A, S?nchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura MF. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med. 2021 10; 11(10):e533.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support